Your browser doesn't support javascript.
loading
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.
Ramos, Isaac Corro; Versteegh, Matthijs M; de Boer, Rudolf A; Koenders, Jolanda M A; Linssen, Gerard C M; Meeder, Joan G; Rutten-van Mölken, Maureen P M H.
Afiliação
  • Ramos IC; Institute for Medical Technology Assessment, Erasmus University Rotterdam, the Netherlands. Electronic address: corroramos@imta.eur.nl.
  • Versteegh MM; Institute for Medical Technology Assessment, Erasmus University Rotterdam, the Netherlands.
  • de Boer RA; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Koenders JMA; Novartis Pharma B.V., Arnhem, the Netherlands.
  • Linssen GCM; Department of Cardiology, Hospital Group Twente, Almelo and Hengelo, the Netherlands.
  • Meeder JG; Department of Cardiology, VieCuri Medical Centre Noord-Limburg, Venlo, the Netherlands.
  • Rutten-van Mölken MPMH; Institute for Medical Technology Assessment, Erasmus University Rotterdam, the Netherlands; Institute of Health Care Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands.
Value Health ; 20(10): 1260-1269, 2017 12.
Article em En | MEDLINE | ID: mdl-29241885
OBJECTIVES: To describe the adaptation of a global health economic model to determine whether treatment with the angiotensin receptor neprilysin inhibitor LCZ696 is cost effective compared with the angiotensin-converting enzyme inhibitor enalapril in adult patients with chronic heart failure with reduced left ventricular ejection fraction in the Netherlands; and to explore the effect of performing the cost-effectiveness analyses according to the new pharmacoeconomic Dutch guidelines (updated during the submission process of LCZ696), which require a value-of-information analysis and the inclusion of indirect medical costs of life-years gained. METHODS: We adapted a UK model to reflect the societal perspective in the Netherlands by including travel expenses, productivity loss, informal care costs, and indirect medical costs during the life-years gained and performed a preliminary value-of-information analysis. RESULTS: The incremental cost-effectiveness ratio obtained was €17,600 per quality-adjusted life-year (QALY) gained. This was robust to changes in most structural assumptions and across different subgroups of patients. Probability sensitivity analysis results showed that the probability that LCZ696 is cost-effective at a €50,000 per QALY threshold is 99.8%, with a population expected value of perfect information of €297,128. On including indirect medical costs of life-years gained, the incremental cost-effectiveness ratio was €26,491 per QALY gained, and LCZ696 was 99.46% cost effective at €50,000 per QALY, with a population expected value of perfect information of €2,849,647. CONCLUSIONS: LCZ696 is cost effective compared with enalapril under the former and current Dutch guidelines. However, the (monetary) consequences of making a wrong decision were considerably different in both scenarios.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tetrazóis / Farmacoeconomia / Modelos Econômicos / Antagonistas de Receptores de Angiotensina / Aminobutiratos / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Guideline / Health_economic_evaluation / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Value Health Assunto da revista: FARMACOLOGIA Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tetrazóis / Farmacoeconomia / Modelos Econômicos / Antagonistas de Receptores de Angiotensina / Aminobutiratos / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Guideline / Health_economic_evaluation / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Value Health Assunto da revista: FARMACOLOGIA Ano de publicação: 2017 Tipo de documento: Article